Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation
Autor: | Guido Kobbe, Ellen Wollmer, A Finck, Markus Ditschkowski, Nadezda Basara, Andreas Neubauer, Martin F. Fey, Peter Dreger, Sebastian Scholl, Helmut R. Salih, Ralf G. Meyer, Michael Lübbert, Jürgen Finke, Andreas Burchert, S K Metzelder, Thomas Pabst, Tobias Schroeder, Katharina Götze, Aristoteles Giagounidis |
---|---|
Rok vydání: | 2017 |
Předmět: |
Oncology
Male Cancer Research Time Factors Medizin Internal tandem duplication Kaplan-Meier Estimate 0302 clinical medicine Recurrence Risk Factors hemic and lymphatic diseases Germany 610 Medicine & health Remission Induction Middle Aged Sorafenib Leukemia Myeloid Acute Treatment Outcome Tandem Repeat Sequences 030220 oncology & carcinogenesis Cohort Disease Progression Female Stem cell Myeloid leukaemia psychological phenomena and processes Flt3 itd medicine.drug Adult Niacinamide medicine.medical_specialty Adolescent Antineoplastic Agents Disease-Free Survival 03 medical and health sciences Young Adult Internal medicine Long term survival medicine Biomarkers Tumor Humans Transplantation Homologous neoplasms Protein Kinase Inhibitors Aged Retrospective Studies business.industry Phenylurea Compounds Transplantation fms-Like Tyrosine Kinase 3 Immunology business 030215 immunology Stem Cell Transplantation |
Zdroj: | European journal of cancer (Oxford, England : 1990). 86 |
ISSN: | 1879-0852 |
Popis: | Background Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD)–positive acute myeloid leukaemia (AML) relapsing after allogeneic stem cell transplantation (allo-SCT) has a dismal prognosis with limited therapeutic options. FLT3-ITD kinase inhibition is a reasonable but palliative experimental treatment alternative in this situation. Information on long-term outcome is not available. Methods We performed a long-term follow-up analysis of a previously reported cohort of 29 FLT3-ITD–positive AML patients, which were treated in relapse after allo-SCT with sorafenib monotherapy. Findings With a median follow-up of 7.5 years, 6 of 29 patients (21%) are still alive. Excluding one patient who received a second allo-SCT, five patients (17%) achieved sustained complete remissions with sorafenib. Four of these patients are in treatment-free remission for a median of 4.4 years. Interpretation Sorafenib may enable cure of a proportion of very poor risk FLT3-ITD–positive AML relapsing after allo-SCT. |
Databáze: | OpenAIRE |
Externí odkaz: |